Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases

Nov 9 (Reuters) - NovoCure Limited NVCR.O:

• NOVOCURE PROVIDES REGULATORY UPDATE ON U.S. FDA PREMARKET APPROVAL APPLICATION FOR OPTUNE MYA® FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER

• NOVOCURE - FDA CITES UNCERTAINTY IN CLINICAL BENEFIT FOR OPTUNE MYA PMA NON-APPROVAL

• NOVOCURE - FDA DOES NOT RAISE SAFETY CONCERNS FOR OPTUNE MYA

• NOVOCURE - TO MEET FDA TO EXPLORE PMA APPROVAL OPTIONS WITHOUT ADDITIONAL STUDIES

• NOVOCURE - RECEIVES FDA NOT APPROVABLE LETTER FOR OPTUNE MYA PMA APPLICATION

Further company coverage: NVCR.O